Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gonadorelin→

Gonadorelin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
33515-09-2
Molecular formula
C55H75N17O13
Molecular weight
1182.31 g/mol
Drug class
Gonadotropin-releasing hormone (GnRH) analoguegonadotropin secretagogue
Mechanism of action
Binds to and activates pituitary GnRH receptors, stimulating synthesis and release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). The response depends on the dose and pattern of administration.
Indications / reported uses
  • Diagnostic assessment of pituitary gonadotroph function in selected endocrine evaluations.
  • Veterinary use to induce LH release and ovulation or manage selected reproductive disorders, according to the authorised species and product.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gonadotropin-releasing-hormone-analog · https://www.ema.europa.eu/en/documents/mrl-report/gonadotrophin-releasing-hormone-gonadorelin-summary-report-committee-veterinary-medicinal-products_en.pdf

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gonadotropin-releasing hormone (GnRH) analogue; gonadotropin secretagogue

Mechanism of action

Binds to and activates pituitary GnRH receptors, stimulating synthesis and release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). The response depends on the dose and pattern of administration.

General use cases

  • Diagnostic assessment of pituitary gonadotroph function in selected endocrine evaluations.
  • Veterinary use to induce LH release and ovulation or manage selected reproductive disorders, according to the authorised species and product.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Gonadorelin Environmental Risk Assessment (ERA) (the Gonadorelin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.